Inflammation plays a key role in the body's defense against pathogens, forming part of a complex series of events that help maintain organ function and systemic balance. While acute inflammation is vital for fighting infections, persistent or chronic inflammation is increasingly linked to the development of various health conditions, including diabetes, atherosclerosis, cardiometabolic diseases, rheumatoid arthritis, and obesity.
C-Reactive Protein (CRP) has long been the primary marker for assessing inflammation. However, recent research highlights the growing importance of glycoproteins and lipoproteins in both acute and chronic inflammation. Notably, inflammation can alter the composition of HDL particles, influencing their pro- or anti-inflammatory behavior.
In this webinar, Bruker will explore how Nuclear Magnetic Resonance (NMR*) technology delivers precise, detailed measurements of glycoproteins and lipoproteins, providing a comprehensive inflammatory profile within minutes. Additionally, Bruker will present how these models have been adapted for benchtop NMR spectrometers, potentially revolutionizing the landscape of NMR-based lipoprotein measurements.
Sign up for this webinar today to explore how Bruker's advancements in NMR technology are set to revolutionize clinical research settings.
Key highlights
- Innovative NMR techniques: Explore Bruker's diffusion and relaxation-edited NMR experiments, which have resulted in a model-free inflammatory panel characterized by SPC1, SPC2, SPC3, GlycA, and GlycB peaks.
- Comprehensive data analysis: Learn how these five parameters contribute to constructing a molecular multivariate map of acute and chronic inflammatory phenotypes, applied across multiple disease and population cohorts (N = 5000).
- Translational technology: Gain insights into the potential of benchtop NMR spectrometers for accurately predicting lipoprotein parameters and fractions.
- Clinical research applications: Discover how self-administered capillary blood samples can replace venipuncture, enabling easier sampling in remote locations or for high-frequency longitudinal studies.
Benefits of attending
- Gain insights into the latest advancements in inflammation disease research and NMR * technology.
- Discover how benchtop NMR technology could pave the way for routine clinical use.
- Explore the potential of non-invasive, rapid, and accurate methods for analyzing inflammation in clinical and research settings.
* Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures
Who should attend?
- Clinical researchers: Biologists, biochemists, and analytical scientists investigating or interested in expanding research into acute and chronic inflammation linked to the onset of cardiovascular disorders, metabolic syndrome, and related fields.
- Graduate students and postdoctoral fellows: Those seeking advanced knowledge and practical skills in applying NMR in human health and inflammation disease.
- Industry professionals: Scientists and R&D personnel in pharmaceutical, biotechnology, and nutritional companies doing research and developing therapeutic and diagnostic solutions related to inflammation
- Scientists working in human metabolomics research seeking to expand their expertise into standardized NMR-based Metabolomics.
About the speaker
Julien Wist, Professor of Computational Spectroscopy | Deputy Director of the Center for Computational & Systems Medicine
Prof. Julien Wist currently serves as the Deputy Director of the Centre for Computational and Systems Medicine at Murdoch University. He also leads the operations and bio-/chem-informatics team at the Australian National Phenome Centre, which includes software engineers, biostatisticians, chemometricians, and data processing experts, all working together to develop analytical pipelines for metabolic phenotyping. Prof. Wist actively contributes to international initiatives focused on creating open-source data analysis and visualization platforms such as nmrdb.org, nmrium.org, and cheminfo.org.
His research primarily revolves around integrating high-fidelity molecular phenotypes to develop translatable methods for clinical applications. Prof. Wist is dedicated to building a comprehensive phenotypic databank of the global population by combining cellular, immunological, and molecular data. His work on SARS-CoV-2 has uncovered vital markers for disease progression, including those related to the acute phase, mortality risk, and post-acute COVID-19 syndrome.
Recently, Prof. Wist and his team made groundbreaking discoveries, identifying and elucidating the structure of 10 new molecules in human urine. These findings revealed an extended RSAD2-dependent antiviral pathway involving the Viperin enzyme, which converts CTP into ddhCTP and its analogs. These discoveries have resulted in two patents in collaboration with industry leaders and have been published in leading international journals.